Ceritinib (LDK378) Cas 1032900-25-6

Ceritinib (LDK378) Cas 1032900-25-6
Ceritinib LDK378 Pharmaceutical Raw Materials Powder for Nsclc CAS 1032900-25-6 Quick Details : ProName: LDK-378,Ceritinib CasNo: 1032900-25-6 Molecular Formula: CHN Appearance: white powders Application: Intermediates Purity: 99% Storage: sealed, keep in the ventilated, dry Description :...
Product Details

Ceritinib LDK378 Pharmaceutical Raw Materials Powder for Nsclc CAS 1032900-25-6

Quick Details:
 ProName: LDK-378,Ceritinib
 CasNo: 1032900-25-6
 Molecular Formula: CHN
 Appearance: white powders
 Application: Intermediates
 Purity: 99%
 Storage: sealed, keep in the ventilated, dry
 Description:
 Ceritinib, also known as LDK378, is a selective inhibitor of ALK1, a target found in metastatic non-small cell lung cancer (NSCLC). In Phase I trials, LDK378 showed a marked clinical response in 78 patients with anaplastic lymphoma kinase positive (ALK+) metastatic non-small cell lung cancer (NSCLC) who had progressed during or after crizotinib therapy or had not been previously treated with crizotinib.

Usage:
Ceritinib is a drug for the treatment of lung cancer. Ceritinib is an ALK inhibitor.Ceritinib was approved in April 2014 by the Food and Drug Administration for the treatment of ALK-positive metastatic non-small cell lung cancer (NSCLC) following treatment with crizotinib.

Application:
 Ceritinib (trade name Zykadia) is a drug for the treatment of a specific type of lung cancer.[1] It is an anaplastic lymphoma kinase (ALK) inhibitor.It was approved in April 2014 by the Food and Drug Administration for the treatment of ALK-positive metastatic non-small cell lung cancer (NSCLC) following treatment with crizotinib.

 

Hot Tags: ceritinib (LDK378) cas 1032900-25-6, China, suppliers, wholesale, buy
Feedback